système rénine-angiotensine; bradykinine; inhibiteur de l'enzyme de conversion; fonction endothéliale; périndopril; Renin-angiotensin system; Bradykinin; Angiotensin converting enzyme inhibitor; Endothelial function; Perindopril
Abstract :
[en] The endothelium plays a vital role as part of the cardiovascular continuum. Risk factors such as hypertension and dyslipidemia unbalance angiotensin II - bradykinin homeostasis, leading to endothelial dysfunction and changes in vascular structure that promote atherosclerosis and thrombosis. When dealing with risk factors, treatment should focus on the prevention and restoration of endothelial function. Not all cardiovascular drugs are able to reverse vascular and structural endothelial dysfunction. Increasing levels of bradykinin is an effect of the use of angiotensin-converting enzyme inhibitors (ACE-Is), and also a fundamental part of their mode of action. The cardiovascular protection observed with ACE-I, and not with sartans, can be explained rationally by the specific effects of bradykinin on the endothelium. In the pharmacological class of ACE-Is, perindopril likely produces the strongest effects on bradykinin, which may explain, at least in part, the documented superiority of this drug in the prevention and treatment of cardiovascular disease. [fr] L’endothélium joue un rôle primordial en tant qu’élément du continuum cardiovasculaire. Les facteurs de risque comme l’hypertension et les dyslipidémies déséquilibrent l’homéostasie angiotensine II – bradykinine, ce qui entraîne une dysfonction endothéliale et des modifications
de la structure vasculaire favorisant l’athérosclérose et les thromboses. Le but du traitement des facteurs de risque doit être la prévention et la restauration de la fonction endothéliale, mais tous les médicaments à visée cardiovasculaire ne sont pas capables d’inverser la dysfonction
endothéliale et les anomalies structurelles vasculaires. L’augmentation des taux de bradykinine est un effet de la prise des inhibiteurs de l’enzyme de conversion (IEC), et représente un élément fondamental de leur mode d’action. La protection cardiovasculaire observée avec les IEC, et
non avec les sartans, peut s’expliquer rationnellement par les effets spécifiques de la bradykinine sur l’endothélium. Dans la classe pharmacologique des IEC, c’est probablement le périndopril qui produit les effets les plus puissants sur la bradykinine, ce qui peut expliquer, au moins en partie, la supériorité documentée de ce médicament dans la prévention et le traitement des maladies cardiovasculaires.
Disciplines :
Urology & nephrology General & internal medicine
Author, co-author :
Lancellotti, Patrizio ; Université de Liège - ULiège > Département des sciences cliniques > Cardiologie - Pathologie spéciale et réhabilitation
ANCION, Arnaud ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Insuffisance cardiaque - Transplantation
D'ORIO, Vincenzo ; Centre Hospitalier Universitaire de Liège - CHU > Autres Services Médicaux > Service des urgences
GACH, Olivier ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Cardiologie interventionnelle
MARECHAL, Patrick ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Cardiologie multidisciplinaire et prévention
KRZESINSKI, Jean-Marie ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service de néphrologie
Language :
French
Title :
Bradykinine et protection cardiovasculaire. Role du perindopril, un inhibiteur de l'enzyme de conversion de l'angiotensine.
Alternative titles :
[en] Bradykinin and cardiovascular protection. Role of perindopril, an inhibitor of angiotensin conversion enzyme
Publication date :
2018
Journal title :
Revue Médicale de Liège
ISSN :
0370-629X
eISSN :
2566-1566
Publisher :
Université de Liège. Revue Médicale de Liège, Liège, Belgium
Furchgott RF, Zawadzki JV. - The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature, 1980, 288, 373-376.
Lüscher TF, Barton M. - Biology of the endothelium. Clin Cardiol, 1997, 20, II3-II10.
Watanabe T, Barker TA, Berk BC. - Angiotensin II and the endothelium: diverse signals and effects. Hypertension, 2005, 45, 163-169.
Tamarat R, Silvestre JS, Durie M, et al. - Angiotensin II angiogenic effect in vivo involves vascular endothelial growth factor-and inflammation-related pathways. Lab Invest, 2002, 82, 747-756
Arenas IA, Xu Y, Lopez-Jaramillo P, et al. - Angiotensin II-induced MMP-2 release from endothelial cells is mediated by TNF-alpha. Am J Physiol Cell Physiol, 2004, 286, C779-C784.
Li D Y, Zhang YC, Philips MI, et al. - Upregulation of endothelial receptor for oxidized low-density lipoprotein (LOX-1) in cultured human coronary artery endothelial cells by angiotensin II type 1 receptor activation. Circ Res, 1999, 84, 1043-1049.
Ridker PM, Gaboury CL, Conlin PR, et al. - Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function. Circulation, 1993, 87, 1969-1973.
Kossmann S, Hu H, Steven S, et al. - Inflammatory monocytes determine endothelial nitric-oxide synthase uncoupling and nitro-oxidative stress induced by angiotensin II. J Biol Chem, 2014, 289, 27540-27550.
Levy BI, Benessiano J, Henrion D, et al. - Chronic blockade of AT2-subtype receptors prevents the effect of angiotensin II on the rat vascular structure. J Clin Invest, 1996, 98, 418-425.
Kayashima Y, Smithies O, Kakoki M. - The kallikrein-kinin system and oxidative stress. Curr Opin Nephrol Hypertens, 2012, 21, 92-96.
Kuhr F, Lowry J, Zhang Y, et al. - Differential regulation of inducible and endothelial nitric oxide synthase by kinin B1 and B2 receptors. Neuropeptides, 2010, 44, 145-154.
Su JB. - Kinins and cardiovascular diseases. Curr Pharm Des, 2006, 12, 3423-3435.
Su JB, Hoüel R, Héloire F, et al. - Stimulation of bradykinin B (1) receptors induces vasodilation in conductance and resistance coronary vessels in conscious dogs: comparison with B (2) receptor stimulation. Circulation, 2000, 101, 1848-1853.
Su JB. - Different cross-talk sites between the renin-angiotensin and the kallikrein-kinin systems. J Renin Angiotensin Aldosterone Syst, 2014, 15, 319-328.
Taddei S, Bortolotto L. - Unraveling the pivotal role of bradykinin in ACE inhibitor activity. Am J Cardiovasc Drugs, 2016, 16, 309-321.
Baudin B, Berard M, Carrier JL, et al. - Vascular origin determines angiotensin I-converting enzyme expression in endothelial cells. Endothelium, 1997, 5, 73-84.
Taddei S, Versari D, Cipriano A, et al. - Identification of a cytochrome P450 2C9-derived endothelium-derived hyperpolarizing factor in essential hypertensive patients. J Am Coll Cardiol, 2006, 48, 508-515.
Bentley JP, Asselbergs FW, Coffey CS, et al. - Cardiovascular risk associated with interactions among polymorphisms in genes from the reninangiotensin, bradykinin, and fibrinolytic systems. PLoS One, 2010, 5, e12757.
Wiman B, Andersson T, Hallqvist J, et al. - Plasma levels of tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart Epidemiology Program (SHEEP) study. Arterioscler Thromb Vasc Biol, 2000, 20, 2019-2023.
Taddei S, Virdis A, Ghiadoni L, et al. - Vitamin C improves endothelium-dependent vasodilation by restoring nitric oxide activity in essential hypertension. Circulation, 1998, 97, 2222-2229.
Hansson GK. - Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med, 2005, 352, 1685-1695.
Virdis A, Ghiadoni L, Taddei S. - Effects of antihypertensive treatment on endothelial function. Curr Hypertens Rep, 2011, 13, 276-281.
Virdis A, Neves MF, Amiri F, et al. - Role of NAD (P) H oxidase on vascular alterations in angiotensin II-infused mice. J Hypertens, 2004, 22, 535-542.
Ceconi C, Francolini G, Olivares A, et al. - Angiotensin converting enzyme (ACE) inhibitors have different selectivity for bradykinin binding sites of human somatic ACE. Eur J Pharmacol, 2007, 577, 1-6.
Ferrari R, Guardigli G, Ceconi C. - Secondary prevention of CAD with ACE inhibitors: a struggle between life and death of the endothelium. Cardiovasc Drug Ther, 2010, 24, 331-339.
You D, Cochain C, Loinard C, et al. - Hypertension impairs postnatal vasculogenesis: role of antihypertensive agents. Hypertension, 2008, 51, 1537-1544.
Tropeano AI, Boutouyrie P, Pannier B, et al. - Brachial pressure-independent reduction in carotid stiffness after long-term angiotensin-converting enzyme inhibition in diabetic hypertensives. Hypertension, 2006, 48, 80-86.
Bruining N, deWinter S, Roelandt J, et al. - Coronary calcium significantly affects quantitative analysis of coronary ultrasound: importance for atherosclerosis progression/regression studies. Coron Artery Dis, 2009, 20, 409-414.
Poulter NR, Wedel H, Dahlöf B et al. - ASCOT Investigators. - Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet, 2005, 366, 907-913.
Williams B, Lacy PS, Thom SM, et al. - CAFE Investigators; Anglo-Scandinavian Cardiac Outcomes Trial Investigators; CAFE Steering Committee and Writing Committee. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation, 2006, 113, 1213-1225.
Patel A, MacMahon S, Chalmers J, et al. - ADVANCE Collaborative Group, Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet, 2007, 370, 829-840.
Fox KM. - Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet, 2003, 362, 782-788.
Scheen AJ, Legrand V. - L'étude clinique du mois. L'étude EUROPA: protection cardio-vasculaire avec le périndopril chez les patients avec coronaropathie stable. Rev Med Liege, 2003, 58, 713-716.
PROGRESS Collaborative Group. - Randomised trial of a perindopril based blood-pressure-lowering regimen among 6, 105 individuals with previous stroke or transient ischaemic attack. Lancet, 2001, 358, 1033-1041.
Scheen AJ. - Etude clinique du mois. Protection secondaire de l'accident vasculaire cérébral par le périndopril: l'étude PROGRESS. Rev Med Liege 2001, 56, 792-795.
Ferrari R. - Effects of angiotensin-converting enzyme inhibition with perindopril on left ventricular remodeling and clinical outcome: results of the randomized Perindopril and Remodeling in Elderly with Acute Myocardial Infarction (PREAMI) Study. Arch Intern Med, 2006, 166, 659-666.
Cleland JG, Tendera M, Adamus J, et al. - The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J, 2006, 27, 2338-2345.
Krzesinski JM, Montrieux Ch, Scheen AJ. - Inhibiteurs de l'enzyme de conversion de l'angiotensine ou antagonistes des récepteurs de l'angiotensine 2 en pathologie cardio-vasculaire et néphrologique: que nous dit l'Evidence Based Medicine ? Rev Med Liege, 2006, 61, 414-422.
